Richard Piekarz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Richard Piekarz has a total of 245 co-authors. Here are the top co-authors by number of shared publications:
- Alice P. Chen
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA
34 shared publications - Lawrence V. Rubinstein
Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD
33 shared publications - James H. Doroshow
Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, USA
29 shared publications - Geraldine O'SUllivan Coyne
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD
28 shared publications Howard Streicher
21 shared publications- Naoko Takebe
National Cancer Institute 2 Division of Cancer Treatment and Diagnosis National Institutes of Health, Bethesda, Maryland
15 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Differentially methylated regions with at least five CpGs, and a mean difference of greater than 20% between day 14 and baseline white blood cells
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Differentially methylated regions with at least five CpGs, and a mean difference of greater than 20% between day 14 and baseline white blood cells
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix S1 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Supplemental methods and figures
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix S1 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Supplemental methods and figures
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Purpose:Succinate dehydrogenase (dSDH)-deficient tumors, including pheochromocytoma/paraganglioma, hereditary leiomyomatosis and renal cell cancer–associated renal cell carcinoma (HLRCC-RCC), and gastrointestinal stromal tumors (GIST) without KIT or platelet-derived growth factor receptor alpha mutations are often resistant to cytotoxic chemotherapy, radiotherapy, and many targeted therapies. We evaluated guadecitabine, a dinucleotide containing the DNA methyltransferase inhibitor decitabine, in these patient populations.Patients and Methods:Phase II study of guadecitabine (subcutaneously, 45 mg/m2/day for 5 consecutive days, planned 28-day cycle) to assess clinical activity (according to RECISTv.1.1) across three strata of patients with dSDH GIST, pheochromocytoma/paraganglioma, or HLRCC-RCC. A Simon optimal two-stage design (target response rate 30% rule out 5%) was used. Biologic correlates (methylation and metabolites) from peripheral blood mononuclear cells (PBMC), serum, and urine were analyzed.Results:Nine patients (7 with dSDH GIST, 1 each with paraganglioma and HLRCC-RCC, 6 females and 3 males, age range 18–57 years) were enrolled. Two patients developed treatment-limiting neutropenia. No partial or complete responses were observed (range 1–17 cycles of therapy). Biologic activity assessed as global demethylation in PBMCs was observed. No clear changes in metabolite concentrations were observed.Conclusions:Guadecitabine was tolerated in patients with dSDH tumors with manageable toxicity. Although 4 of 9 patients had prolonged stable disease, there were no objective responses. Thus, guadecitabine did not meet the target of 30% response rate across dSDH tumors at this dose, although signs of biologic activity were noted.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Purpose:Succinate dehydrogenase (dSDH)-deficient tumors, including pheochromocytoma/paraganglioma, hereditary leiomyomatosis and renal cell cancer–associated renal cell carcinoma (HLRCC-RCC), and gastrointestinal stromal tumors (GIST) without KIT or platelet-derived growth factor receptor alpha mutations are often resistant to cytotoxic chemotherapy, radiotherapy, and many targeted therapies. We evaluated guadecitabine, a dinucleotide containing the DNA methyltransferase inhibitor decitabine, in these patient populations.Patients and Methods:Phase II study of guadecitabine (subcutaneously, 45 mg/m2/day for 5 consecutive days, planned 28-day cycle) to assess clinical activity (according to RECISTv.1.1) across three strata of patients with dSDH GIST, pheochromocytoma/paraganglioma, or HLRCC-RCC. A Simon optimal two-stage design (target response rate 30% rule out 5%) was used. Biologic correlates (methylation and metabolites) from peripheral blood mononuclear cells (PBMC), serum, and urine were analyzed.Results:Nine patients (7 with dSDH GIST, 1 each with paraganglioma and HLRCC-RCC, 6 females and 3 males, age range 18–57 years) were enrolled. Two patients developed treatment-limiting neutropenia. No partial or complete responses were observed (range 1–17 cycles of therapy). Biologic activity assessed as global demethylation in PBMCs was observed. No clear changes in metabolite concentrations were observed.Conclusions:Guadecitabine was tolerated in patients with dSDH tumors with manageable toxicity. Although 4 of 9 patients had prolonged stable disease, there were no objective responses. Thus, guadecitabine did not meet the target of 30% response rate across dSDH tumors at this dose, although signs of biologic activity were noted.
- Open Access
Cutaneous T-Cell Lymphoma: Yin-Yang Effects of Transcription Factors HLF and NFIL3 in Regulation of Malignant T-Cell Markers in the Context of HDAC Inhibitor Romidepsin Treatment
Background/Objectives: We examined the in vivo effects of successive treatments with the histone deacetylase (HDAC) inhibitor romidepsin in patients with cutaneous T-cell lymphoma (CTCL), using changes in gene expression in peripheral blood mononuclear cells (PBMCs). Methods: Exploiting data from a highly responsive CTCL patient through 12 months of treatment, we identified a malignant cell predictor (MCP), a gene signature associated with the diminishing numbers of circulating malignant cells. Results: The MCP was successfully validated in the patient’s relapse sample 9 months after treatment was terminated and via an independent set of CTCL patient samples. Conclusions: The MCP set of genes contained novel CTCL markers, including membrane-associated proteins not normally expressed in lymphocytes. A subclass of those markers was also detectable in residual malignant cells undetected by flow cytometry in remission samples from a patient who relapsed 10 months later. We identified a subset of transcriptional regulators, miRNAs and methylation patterns associated with the effect of progressive treatments revealing potential mechanisms of transcriptional dysregulation and functional effects in the malignant cells. We demonstrate a role for transcriptional activator HLF, over-expressed in malignant cells, and downregulated transcriptional-suppressor and immune-modulator NFIL3, as regulators of CTCL-specific genes.
Open AccessCutaneous T-Cell Lymphoma: Yin-Yang Effects of Transcription Factors HLF and NFIL3 in Regulation of Malignant T-Cell Markers in the Context of HDAC Inhibitor Romidepsin Treatment
Background/Objectives: We examined the in vivo effects of successive treatments with the histone deacetylase (HDAC) inhibitor romidepsin in patients with cutaneous T-cell lymphoma (CTCL), using changes in gene expression in peripheral blood mononuclear cells (PBMCs). Methods: Exploiting data from a highly responsive CTCL patient through 12 months of treatment, we identified a malignant cell predictor (MCP), a gene signature associated with the diminishing numbers of circulating malignant cells. Results: The MCP was successfully validated in the patient’s relapse sample 9 months after treatment was terminated and via an independent set of CTCL patient samples. Conclusions: The MCP set of genes contained novel CTCL markers, including membrane-associated proteins not normally expressed in lymphocytes. A subclass of those markers was also detectable in residual malignant cells undetected by flow cytometry in remission samples from a patient who relapsed 10 months later. We identified a subset of transcriptional regulators, miRNAs and methylation patterns associated with the effect of progressive treatments revealing potential mechanisms of transcriptional dysregulation and functional effects in the malignant cells. We demonstrate a role for transcriptional activator HLF, over-expressed in malignant cells, and downregulated transcriptional-suppressor and immune-modulator NFIL3, as regulators of CTCL-specific genes.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Prior taxane-based therapy and duration for patients receiving the nilotinib-paclitaxel combination
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Prior taxane-based therapy and duration for patients receiving the nilotinib-paclitaxel combination
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
All adverse events at least possibly attributed to study drugs
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
All adverse events at least possibly attributed to study drugs
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Dose limiting toxicities for the nilotinib-paclitaxel combination
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Dose limiting toxicities for the nilotinib-paclitaxel combination
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Paclitaxel dose intensities during DLT evaluation
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Paclitaxel dose intensities during DLT evaluation
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Peripheral neuropathy incidence following nilotinib-paclitaxel combination therapy or paclitaxel monotherapy
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Peripheral neuropathy incidence following nilotinib-paclitaxel combination therapy or paclitaxel monotherapy